Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE 
FendX Technologies Announces Non-Brokered Private Placement with Strategic Investors
Oakville, Ontario--(Newsfile Corp. - December 20, 2023) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or...
National Minority Quality Forum Announces Published Results of Baseline Minority and Rural Coronavirus Insights Study in Population Health Management
Study finds that despite past headlines, COVID-19 infection rates are higher amongst people of color.Washington, D.C.--(Newsfile Corp. - December 20,...
TravelNurseSource Announces Spring Scholarship Winner
LANCASTER, PA / ACCESSWIRE / December 20, 2023 / We are thrilled to announce that Stephanie Nwegbu has been chosen...
Tenon Medical Announces Participation in Two Key Immersive Webinar Physician Training Programs Featuring the Company’s Catamaran(R) SI Joint Fusion System
~ Training Programs Led by Dr. Matthew Davies from Duluth, MN and Included Simulated Catamaran Procedure ~~ Reached Approximately 60...
Lindis Blood Care Announces Last Patient Out in Multicenter Clinical Certification Study REMOVE with CATUVAB(R) to Eliminate Tumor Cells from Surgical Blood
BERLIN, GERMANY / ACCESSWIRE / December 20, 2023 / Lindis Blood Care, a company aiming to set a new standard...
Leafbuyer Technologies, Inc. Announces Best Sales Month in Company History
Technology Company Records All Time Record Monthly SalesDENVER, CO / ACCESSWIRE / December 20, 2023 / Leafbuyer Technologies, Inc. ("Leafbuyer"...
Success Beyond Startup: Nurturing Growth as a Co-Founder with Kilo Health
VILNIUS, LITHUANIA / ACCESSWIRE / December 20, 2023 / From developing healthcare systems to personalized fitness apps such as Joggo,...
MindBio Therapeutics CEO Provides End of Year Video Update on Phase 2 Clinical Trials
VANCOUVER, BC / ACCESSWIRE / December 20, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), Chief Executive Officer...
BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset
In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s combination regimen exceeded that of...
Martin Glensbjerg takes up new position at ChemoMetec
ANNOUNCEMENT NO. 248 20 December 2023 Martin Glensbjerg takes up a new role in ChemoMetec COO and deputy chairman of...
Kriya to Present at the J.P. Morgan 42nd Annual Healthcare Conference
PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical...
Shockwave Medical to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
SANTA CLARA, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and...
Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week
TransCon CNP is the first investigational product to demonstrate improvements in health-related quality of life and disease impacts in children...
Kane Biotech Receives Offer for its Interest in STEM Animal Health
Proposed transaction allows for sharpened focus on Human HealthWINNIPEG, Manitoba, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE...
Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference
MARLBOROUGH, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary DysmenorrheaSAN DIEGO, Dec. 20,...
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
New clinical data showed that Lomecel-B™ improved cognitive function in multiple measures in a dose-response fashion Caregiver ratings documented improved quality...
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS
Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents...
Boomerang Medical’s IBD Neuromodulation Study Successfully Completes Enrollment Milestone
Pioneering Bioelectronic Research Advances in the Fight Against Inflammatory Bowel DiseaseMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Boomerang Medical, Inc., a women-led bioelectronic medicine...
Poolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis Update
Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AIRSV drug candidates with the highest probability of success...